{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:41:16Z","timestamp":1790707276056,"version":"4.1.0"},"reference-count":206,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Immunol Res"],"DOI":"10.1007\/s12026-026-09756-4","type":"journal-article","created":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T10:25:11Z","timestamp":1773656711000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The Fas-FasL system: from apoptosis regulator to therapeutic target in autoimmunity, cancer, and transplantation"],"prefix":"10.1007","volume":"74","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9260-0043","authenticated-orcid":false,"given":"Mohamed","family":"Gadelkarim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4804-504X","authenticated-orcid":false,"given":"Ahmed","family":"Elsayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abubakar","family":"Nazir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousif","family":"Elsayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayham","family":"Habashneh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omer","family":"Iqbal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Badi","family":"Rawashdeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,16]]},"reference":[{"key":"9756_CR1","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1158\/2159-8290.CD-20-0756","volume":"11","author":"R Upadhyay","year":"2021","unstructured":"Upadhyay R, Boiarsky JA, Pantsulaia G, Svensson-Arvelund J, Lin MJ, Wroblewska A, et al. A critical role for Fas-mediated off-target tumor killing in T-cell immunotherapy. Cancer Discov. 2021;11:599\u2013613. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-0756.","journal-title":"Cancer Discov"},{"key":"9756_CR2","doi-asserted-by":"publisher","unstructured":"Volpe E, Sambucci M, Battistini L, Borsellino G. Fas\u2013Fas Ligand: Checkpoint of T Cell Functions in Multiple Sclerosis. Front Immunol 2016;7. https:\/\/doi.org\/10.3389\/fimmu.2016.00382.","DOI":"10.3389\/fimmu.2016.00382"},{"key":"9756_CR3","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1615\/CritRevImmunol.2014009988","volume":"34","author":"R Arakaki","year":"2014","unstructured":"Arakaki R, Yamada A, Kudo Y, Hayashi Y, Ishimaru N. Mechanism of activation-induced cell death of T cells and regulation of FasL expression. Crit Rev Immunol. 2014;34:301\u201314. https:\/\/doi.org\/10.1615\/CritRevImmunol.2014009988.","journal-title":"Crit Rev Immunol"},{"key":"9756_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/cells13211814","volume":"13","author":"K Seyrek","year":"2024","unstructured":"Seyrek K, Espe J, Reiss E, Lavrik IN. The crosstalk of apoptotic and non-apoptotic signaling in CD95 system. Cells. 2024;13:1814. https:\/\/doi.org\/10.3390\/cells13211814.","journal-title":"Cells"},{"key":"9756_CR5","doi-asserted-by":"publisher","unstructured":"Menezes SM, Leal FE, Dierckx T, Khouri R, Decanine D, Silva-Santos G, et al. A Fashi Lymphoproliferative Phenotype Reveals Non-Apoptotic Fas Signaling in HTLV-1-Associated Neuroinflammation. Front Immunol 2017;8. https:\/\/doi.org\/10.3389\/fimmu.2017.00097.","DOI":"10.3389\/fimmu.2017.00097"},{"key":"9756_CR6","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/cdd.2011.155","volume":"19","author":"IN Lavrik","year":"2012","unstructured":"Lavrik IN, Krammer PH. Regulation of CD95\/Fas signaling at the DISC. Cell Death Differ. 2012;19:36\u201341. https:\/\/doi.org\/10.1038\/cdd.2011.155.","journal-title":"Cell Death Differ"},{"key":"9756_CR7","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1002\/cncr.20270","volume":"100","author":"R Kim","year":"2004","unstructured":"Kim R, Emi M, Tanabe K, Uchida Y, Toge T. The role of Fas ligand and transforming growth factor \u03b2 in tumor progression: molecular mechanisms of immune privilege via Fas-mediated apoptosis and potential targets for cancer therapy. Cancer. 2004;100:2281\u201391. https:\/\/doi.org\/10.1002\/cncr.20270.","journal-title":"Cancer"},{"key":"9756_CR8","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1002\/med.20025","volume":"25","author":"M Scholz","year":"2005","unstructured":"Scholz M, Cinatl J. Fas\/FasL interaction: a novel immune therapy approach with immobilized biologicals. Med Res Rev. 2005;25:331\u201342. https:\/\/doi.org\/10.1002\/med.20025.","journal-title":"Med Res Rev"},{"key":"9756_CR9","first-page":"5","volume":"17","author":"L Owen-Schaub","year":"2000","unstructured":"Owen-Schaub L, Chan H, Cusack JC, Roth J, Hill LL. Fas and Fas ligand interactions in malignant disease. Int J Oncol. 2000;17:5\u201312.","journal-title":"Int J Oncol"},{"key":"9756_CR10","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1146\/annurev.genet.33.1.29","volume":"33","author":"S Nagata","year":"1999","unstructured":"Nagata S. Fas ligand-induced apoptosis. Annu Rev Genet. 1999;33:29\u201355. https:\/\/doi.org\/10.1146\/annurev.genet.33.1.29.","journal-title":"Annu Rev Genet"},{"key":"9756_CR11","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/35037728","volume":"407","author":"PH Krammer","year":"2000","unstructured":"Krammer PH. CD95\u2019s deadly mission in the immune system. Nature. 2000;407:789\u201395. https:\/\/doi.org\/10.1038\/35037728.","journal-title":"Nature"},{"key":"9756_CR12","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.cell.2007.04.031","volume":"129","author":"ME Peter","year":"2007","unstructured":"Peter ME, Budd RC, Desbarats J, Hedrick SM, Hueber A-O, Newell MK, et al. The CD95 receptor: apoptosis revisited. Cell. 2007;129:447\u201350. https:\/\/doi.org\/10.1016\/j.cell.2007.04.031.","journal-title":"Cell"},{"key":"9756_CR13","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.immuni.2009.01.001","volume":"30","author":"A Strasser","year":"2009","unstructured":"Strasser A, Jost PJ, Nagata S. The many roles of FAS receptor signaling in the immune system. Immunity. 2009;30:180\u201392. https:\/\/doi.org\/10.1016\/j.immuni.2009.01.001.","journal-title":"Immunity"},{"key":"9756_CR14","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1038\/23730","volume":"400","author":"X-M Yin","year":"1999","unstructured":"Yin X-M, Wang K, Gross A, Zhao Y, Zinkel S, Klocke B, et al. Bid-deficient mice are resistant to Fas-induced hepatocellular apoptosis. Nature. 1999;400:886\u201391. https:\/\/doi.org\/10.1038\/23730.","journal-title":"Nature"},{"key":"9756_CR15","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.cell.2007.03.017","volume":"129","author":"T Kaufmann","year":"2007","unstructured":"Kaufmann T, Tai L, Ekert PG, Huang DCS, Norris F, Lindemann RK, et al. The BH3-only protein Bid is dispensable for DNA damage- and replicative stress-induced apoptosis or cell-cycle arrest. Cell. 2007;129:423\u201333. https:\/\/doi.org\/10.1016\/j.cell.2007.03.017.","journal-title":"Cell"},{"key":"9756_CR16","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.2337\/db07-1692","volume":"57","author":"MD McKenzie","year":"2008","unstructured":"McKenzie MD, Carrington EM, Kaufmann T, Strasser A, Huang DCS, Kay TWH, et al. Proapoptotic BH3-only protein Bid is essential for death receptor\u2013induced apoptosis of pancreatic \u03b2-cells. Diabetes. 2008;57:1284\u201392. https:\/\/doi.org\/10.2337\/db07-1692.","journal-title":"Diabetes"},{"key":"9756_CR17","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1101\/gad.10.22.2859","volume":"10","author":"K Wang","year":"1996","unstructured":"Wang K, Yin XM, Chao DT, Milliman CL, Korsmeyer SJ. BID: a novel BH3 domain-only death agonist. Genes Dev. 1996;10:2859\u201369. https:\/\/doi.org\/10.1101\/gad.10.22.2859.","journal-title":"Genes Dev"},{"key":"9756_CR18","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1038\/35080103","volume":"2","author":"M Holcik","year":"2001","unstructured":"Holcik M, Korneluk RG. XIAP, the guardian angel. Nat Rev Mol Cell Biol. 2001;2:550\u20136. https:\/\/doi.org\/10.1038\/35080103.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"9756_CR19","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/nrm1621","volume":"6","author":"DL Vaux","year":"2005","unstructured":"Vaux DL, Silke J. IAPs, RINGs and ubiquitylation. Nat Rev Mol Cell Biol. 2005;6:287\u201397. https:\/\/doi.org\/10.1038\/nrm1621.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"9756_CR20","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S0092-8674(00)00008-8","volume":"102","author":"C Du","year":"2000","unstructured":"Du C, Fang M, Li Y, Li L, Wang X. Smac, a mitochondrial protein that promotes cytochrome c\u2013dependent caspase activation by eliminating IAP inhibition. Cell. 2000;102:33\u201342. https:\/\/doi.org\/10.1016\/S0092-8674(00)00008-8.","journal-title":"Cell"},{"key":"9756_CR21","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S0092-8674(00)00009-X","volume":"102","author":"AM Verhagen","year":"2000","unstructured":"Verhagen AM, Ekert PG, Pakusch M, Silke J, Connolly LM, Reid GE, et al. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell. 2000;102:43\u201353. https:\/\/doi.org\/10.1016\/S0092-8674(00)00009-X.","journal-title":"Cell"},{"key":"9756_CR22","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1038\/nature08229","volume":"460","author":"PJ Jost","year":"2009","unstructured":"Jost PJ, Grabow S, Gray D, McKenzie MD, Nachbur U, Huang DCS, et al. XIAP discriminates between type I and type II FAS-induced apoptosis. Nature. 2009;460:1035\u20139. https:\/\/doi.org\/10.1038\/nature08229.","journal-title":"Nature"},{"key":"9756_CR23","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1517\/14728222.2011.628937","volume":"16","author":"M Villa-Morales","year":"2012","unstructured":"Villa-Morales M, Fern\u00e1ndez-Piqueras J. Targeting the Fas\/FasL signaling pathway in cancer therapy. Expert Opin Ther Targets. 2012;16:85\u2013101. https:\/\/doi.org\/10.1517\/14728222.2011.628937.","journal-title":"Expert Opin Ther Targets"},{"key":"9756_CR24","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.coph.2004.03.008","volume":"4","author":"A Houston","year":"2004","unstructured":"Houston A, O\u2019Connell J. The Fas signalling pathway and its role in the pathogenesis of cancer. Curr Opin Pharmacol. 2004;4:321\u20136. https:\/\/doi.org\/10.1016\/j.coph.2004.03.008.","journal-title":"Curr Opin Pharmacol"},{"key":"9756_CR25","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jhep.2006.07.032","volume":"46","author":"M Nakamura","year":"2007","unstructured":"Nakamura M, Nagano H, Sakon M, Yamamoto T, Ota H, Wada H, et al. Role of the Fas\/FasL pathway in combination therapy with interferon-\u03b1 and fluorouracil against hepatocellular carcinoma in vitro. J Hepatol. 2007;46:77\u201388. https:\/\/doi.org\/10.1016\/j.jhep.2006.07.032.","journal-title":"J Hepatol"},{"key":"9756_CR26","doi-asserted-by":"publisher","first-page":"G354","DOI":"10.1152\/ajpgi.2000.278.3.G354","volume":"278","author":"MJ Pinkoski","year":"2000","unstructured":"Pinkoski MJ, Brunner T, Green DR, Lin T. Fas and Fas ligand in gut and liver. Am J Physiol Gastrointest Liver Physiol. 2000;278:G354\u201366. https:\/\/doi.org\/10.1152\/ajpgi.2000.278.3.G354.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"9756_CR27","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.bj.2021.06.005","volume":"44","author":"A Magerus","year":"2021","unstructured":"Magerus A, Bercher-Brayer C, Rieux-Laucat F. The genetic landscape of the FAS pathway deficiencies. Biomed J. 2021;44:388\u201399. https:\/\/doi.org\/10.1016\/j.bj.2021.06.005.","journal-title":"Biomed J"},{"key":"9756_CR28","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.reprotox.2014.10.013","volume":"50","author":"S Qi","year":"2014","unstructured":"Qi S, Fu W, Wang C, Liu C, Quan C, Kourouma A, et al. BPA-induced apoptosis of rat Sertoli cells through Fas\/FasL and JNKs\/p38 MAPK pathways. Reprod Toxicol. 2014;50:108\u201316. https:\/\/doi.org\/10.1016\/j.reprotox.2014.10.013.","journal-title":"Reprod Toxicol"},{"key":"9756_CR29","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1146\/annurev.immunol.18.1.621","volume":"18","author":"M Karin","year":"2000","unstructured":"Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-\u03baB activity. Annu Rev Immunol. 2000;18:621\u201363. https:\/\/doi.org\/10.1146\/annurev.immunol.18.1.621.","journal-title":"Annu Rev Immunol"},{"key":"9756_CR30","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1083\/jcb.200401036","volume":"166","author":"S Kreuz","year":"2004","unstructured":"Kreuz S, Siegmund D, Rumpf J-J, Samel D, Leverkus M, Janssen O, et al. NF\u03baB activation by Fas is mediated through FADD, caspase-8, and RIP and is inhibited by FLIP. J Cell Biol. 2004;166:369\u201380. https:\/\/doi.org\/10.1083\/jcb.200401036.","journal-title":"J Cell Biol"},{"key":"9756_CR31","doi-asserted-by":"publisher","first-page":"46639","DOI":"10.1074\/jbc.M105102200","volume":"276","author":"FC Kischkel","year":"2001","unstructured":"Kischkel FC, Lawrence DA, Tinel A, LeBlanc H, Virmani A, Schow P, et al. Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8. J Biol Chem. 2001;276:46639\u201346. https:\/\/doi.org\/10.1074\/jbc.M105102200.","journal-title":"J Biol Chem"},{"key":"9756_CR32","doi-asserted-by":"publisher","first-page":"4520","DOI":"10.1093\/emboj\/cdf441","volume":"21","author":"MR Sprick","year":"2002","unstructured":"Sprick MR. Caspase-10 is recruited to and activated at the native TRAIL and CD95 death-inducing signalling complexes in a FADD-dependent manner but can not functionally substitute caspase-8. EMBO J. 2002;21:4520\u201330. https:\/\/doi.org\/10.1093\/emboj\/cdf441.","journal-title":"EMBO J"},{"key":"9756_CR33","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.cellsig.2009.09.016","volume":"22","author":"P Wisniewski","year":"2010","unstructured":"Wisniewski P, Ellert-Miklaszewska A, Kwiatkowska A, Kaminska B. Non-apoptotic Fas signaling regulates invasiveness of glioma cells and modulates MMP-2 activity via NF\u03baB-TIMP-2 pathway. Cell Signal. 2010;22:212\u201320. https:\/\/doi.org\/10.1016\/j.cellsig.2009.09.016.","journal-title":"Cell Signal"},{"key":"9756_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s12858-018-0102-z","volume":"19","author":"Y Hou","year":"2018","unstructured":"Hou Y, Liang D, Liu Y, Chen H, Lou X. Up-regulation of DcR3 in microbial toxins-stimulated HUVECs involves NF-\u03baB signalling. BMC Biochem. 2018;19:13. https:\/\/doi.org\/10.1186\/s12858-018-0102-z.","journal-title":"BMC Biochem"},{"key":"9756_CR35","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.cellsig.2014.11.014","volume":"27","author":"L Zhang","year":"2015","unstructured":"Zhang L, Dittmer MR, Blackwell K, Workman LM, Hostager B, Habelhah H. TRAIL activates JNK and NF-\u03baB through RIP1-dependent and -independent pathways. Cell Signal. 2015;27:306\u201314. https:\/\/doi.org\/10.1016\/j.cellsig.2014.11.014.","journal-title":"Cell Signal"},{"key":"9756_CR36","doi-asserted-by":"publisher","unstructured":"Guo Y, Pan W, Liu S, Shen Z, Xu Y, Hu L. ERK\/MAPK signalling pathway and tumorigenesis (Review). Exp Ther Med 2020. https:\/\/doi.org\/10.3892\/etm.2020.8454.","DOI":"10.3892\/etm.2020.8454"},{"key":"9756_CR37","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1126\/science.281.5384.1860","volume":"281","author":"HY Chang","year":"1998","unstructured":"Chang HY, Nishitoh H, Yang X, Ichijo H, Baltimore D. Activation of apoptosis signal-regulating kinase 1 (ASK1) by the adapter protein Daxx. Science. 1998;281:1860\u20133. https:\/\/doi.org\/10.1126\/science.281.5384.1860.","journal-title":"Science"},{"key":"9756_CR38","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1038\/ncb2362","volume":"13","author":"MA O\u2019Donnell","year":"2011","unstructured":"O\u2019Donnell MA, Perez-Jimenez E, Oberst A, Ng A, Massoumi R, Xavier R, et al. Caspase 8 inhibits programmed necrosis by processing CYLD. Nat Cell Biol. 2011;13:1437\u201342. https:\/\/doi.org\/10.1038\/ncb2362.","journal-title":"Nat Cell Biol"},{"key":"9756_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2011.93","volume":"2","author":"AMM Kober","year":"2011","unstructured":"Kober AMM, Legewie S, Pforr C, Fricker N, Eils R, Krammer PH, et al. Caspase-8 activity has an essential role in CD95\/Fas-mediated MAPK activation. Cell Death Dis. 2011;2:e212. https:\/\/doi.org\/10.1038\/cddis.2011.93.","journal-title":"Cell Death Dis"},{"key":"9756_CR40","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1038\/emboj.2011.85","volume":"30","author":"J Staal","year":"2011","unstructured":"Staal J, Driege Y, Bekaert T, Demeyer A, Muyllaert D, Van Damme P, et al. T-cell receptor-induced JNK activation requires proteolytic inactivation of CYLD by MALT1: CYLD is cleaved by MALT1. EMBO J. 2011;30:1742\u201352. https:\/\/doi.org\/10.1038\/emboj.2011.85.","journal-title":"EMBO J"},{"key":"9756_CR41","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1038\/s41556-021-00732-8","volume":"23","author":"G Zhu","year":"2021","unstructured":"Zhu G, Herlyn M, Yang X. TRIM15 and CYLD regulate ERK activation via lysine-63-linked polyubiquitination. Nat Cell Biol. 2021;23:978\u201391. https:\/\/doi.org\/10.1038\/s41556-021-00732-8.","journal-title":"Nat Cell Biol"},{"key":"9756_CR42","doi-asserted-by":"publisher","first-page":"27179","DOI":"10.1074\/jbc.M414361200","volume":"280","author":"R Reinehr","year":"2005","unstructured":"Reinehr R, Becker S, Eberle A, Grether-Beck S, H\u00e4ussinger D. Involvement of NADPH oxidase isoforms and Src family kinases in CD95-dependent hepatocyte apoptosis. J Biol Chem. 2005;280:27179\u201394. https:\/\/doi.org\/10.1074\/jbc.M414361200.","journal-title":"J Biol Chem"},{"key":"9756_CR43","doi-asserted-by":"publisher","first-page":"19072","DOI":"10.1073\/pnas.1116946108","volume":"108","author":"N Khadra","year":"2011","unstructured":"Khadra N, Bresson-Bepoldin L, Penna A, Chaigne-Delalande B, S\u00e9gui B, Levade T, et al. CD95 triggers Orai1-mediated localized Ca2+ entry, regulates recruitment of protein kinase C (PKC) \u03b22, and prevents death-inducing signaling complex formation. Proc Natl Acad Sci. 2011;108:19072\u20137. https:\/\/doi.org\/10.1073\/pnas.1116946108.","journal-title":"Proc Natl Acad Sci"},{"key":"9756_CR44","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.3002027","volume":"21","author":"S Tauzin","year":"2023","unstructured":"Tauzin S, Chaigne-Delalande B, Selva E, Khadra N, Daburon S, Contin-Bordes C, et al. Correction: the naturally processed CD95L elicits a c-Yes\/calcium\/PI3K-driven cell migration pathway. PLoS Biol. 2023;21:e3002027. https:\/\/doi.org\/10.1371\/journal.pbio.3002027.","journal-title":"PLoS Biol"},{"key":"9756_CR45","doi-asserted-by":"publisher","first-page":"6711","DOI":"10.1158\/0008-5472.CAN-13-1794","volume":"73","author":"M Malleter","year":"2013","unstructured":"Malleter M, Tauzin S, Bessede A, Castellano R, Goubard A, Godey F, et al. CD95L cell surface cleavage triggers a prometastatic signaling pathway in triple-negative breast cancer. Cancer Res. 2013;73:6711\u201321. https:\/\/doi.org\/10.1158\/0008-5472.CAN-13-1794.","journal-title":"Cancer Res"},{"key":"9756_CR46","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.ccr.2008.02.003","volume":"13","author":"S Kleber","year":"2008","unstructured":"Kleber S, Sancho-Martinez I, Wiestler B, Beisel A, Gieffers C, Hill O, et al. Yes and PI3K bind CD95 to signal invasion of glioblastoma. Cancer Cell. 2008;13:235\u201348. https:\/\/doi.org\/10.1016\/j.ccr.2008.02.003.","journal-title":"Cancer Cell"},{"key":"9756_CR47","doi-asserted-by":"publisher","first-page":"3839","DOI":"10.1083\/jcb.201805071","volume":"217","author":"L Gagnoux-Palacios","year":"2018","unstructured":"Gagnoux-Palacios L, Awina H, Audebert S, Rossin A, Mondin M, Borgese F, et al. Cell polarity and adherens junction formation inhibit epithelial Fas cell death receptor signaling. J Cell Biol. 2018;217:3839\u201352. https:\/\/doi.org\/10.1083\/jcb.201805071.","journal-title":"J Cell Biol"},{"key":"9756_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2021.103538","volume":"24","author":"J-P Gu\u00e9gan","year":"2021","unstructured":"Gu\u00e9gan J-P, Pollet J, Ginestier C, Charafe-Jauffret E, Peter ME, Legembre P. CD95\/Fas suppresses NF-\u03baB activation through recruitment of KPC2 in a CD95L\/FasL-independent mechanism. iScience. 2021;24:103538. https:\/\/doi.org\/10.1016\/j.isci.2021.103538.","journal-title":"iScience"},{"key":"9756_CR49","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1084\/jem.182.5.1223","volume":"182","author":"PR Galle","year":"1995","unstructured":"Galle PR, Hofmann WJ, Walczak H, Schaller H, Otto G, Stremmel W, et al. Involvement of the CD95 (APO-1\/Fas) receptor and ligand in liver damage. J Exp Med. 1995;182:1223\u201330. https:\/\/doi.org\/10.1084\/jem.182.5.1223.","journal-title":"J Exp Med"},{"key":"9756_CR50","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1002\/hep.21201","volume":"43","author":"CS Guy","year":"2006","unstructured":"Guy CS, Wang J, Michalak TI. Hepatocytes as cytotoxic effector cells can induce cell death by CD95 ligand-mediated pathway. Hepatol Baltim Md. 2006;43:1231\u201340. https:\/\/doi.org\/10.1002\/hep.21201.","journal-title":"Hepatol Baltim Md"},{"key":"9756_CR51","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1083\/jcb.133.2.335","volume":"133","author":"LE French","year":"1996","unstructured":"French LE, Hahne M, Viard I, Radlgruber G, Zanone R, Becker K, et al. Fas and Fas ligand in embryos and adult mice: ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover. J Cell Biol. 1996;133:335\u201343. https:\/\/doi.org\/10.1083\/jcb.133.2.335.","journal-title":"J Cell Biol"},{"key":"9756_CR52","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1126\/science.270.5239.1189","volume":"270","author":"TS Griffith","year":"1995","unstructured":"Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science. 1995;270:1189\u201392. https:\/\/doi.org\/10.1126\/science.270.5239.1189.","journal-title":"Science"},{"key":"9756_CR53","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.immuni.2007.03.016","volume":"26","author":"PB Stranges","year":"2007","unstructured":"Stranges PB, Watson J, Cooper CJ, Choisy-Rossi C-M, Stonebraker AC, Beighton RA, et al. Elimination of antigen-presenting cells and autoreactive T cells by Fas contributes to prevention of autoimmunity. Immunity. 2007;26:629\u201341. https:\/\/doi.org\/10.1016\/j.immuni.2007.03.016.","journal-title":"Immunity"},{"key":"9756_CR54","doi-asserted-by":"publisher","DOI":"10.1186\/s12865-023-00544-5","volume":"24","author":"I Lindrova","year":"2023","unstructured":"Lindrova I, Kolackova M, Svadlakova T, Vankova R, Chmelarova M, Rosecka M, et al. Unsolved mystery of Fas: mononuclear cells may have trouble dying in patients with Sj\u00f6gren\u2019s syndrome. BMC Immunol. 2023;24:12. https:\/\/doi.org\/10.1186\/s12865-023-00544-5.","journal-title":"BMC Immunol"},{"key":"9756_CR55","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241512155","volume":"24","author":"JM Sun","year":"2023","unstructured":"Sun JM, Chow W-Y, Xu G, Hicks MJ, Nakka M, Shen J, et al. The role of FAS receptor methylation in osteosarcoma metastasis. Int J Mol Sci. 2023;24:12155. https:\/\/doi.org\/10.3390\/ijms241512155.","journal-title":"Int J Mol Sci"},{"key":"9756_CR56","doi-asserted-by":"publisher","DOI":"10.1186\/s10020-022-00560-y","volume":"28","author":"Y Liu","year":"2022","unstructured":"Liu Y, Li X, Zhou X, Wang J, Ao X. FADD as a key molecular player in cancer progression. Mol Med. 2022;28:132. https:\/\/doi.org\/10.1186\/s10020-022-00560-y.","journal-title":"Mol Med"},{"key":"9756_CR57","doi-asserted-by":"publisher","first-page":"2886","DOI":"10.1182\/blood.v97.9.2886","volume":"97","author":"C Schmaltz","year":"2001","unstructured":"Schmaltz C, Alpdogan O, Horndasch KJ, Muriglan SJ, Kappel BJ, Teshima T, et al. Differential use of Fas ligand and perforin cytotoxic pathways by donor T cells in graft-versus-host disease and graft-versus-leukemia effect. Blood. 2001;97:2886\u201395. https:\/\/doi.org\/10.1182\/blood.v97.9.2886.","journal-title":"Blood"},{"key":"9756_CR58","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1182\/bloodadvances.2022008495","volume":"7","author":"P Shrestha","year":"2023","unstructured":"Shrestha P, Turan A, Batra L, Gulen AE, Sun Z, Tan H, et al. Engineering donor lymphocytes with Fas ligand protein effectively prevents acute graft-versus-host disease. Blood Adv. 2023;7:2181\u201395. https:\/\/doi.org\/10.1182\/bloodadvances.2022008495.","journal-title":"Blood Adv"},{"key":"9756_CR59","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2025.2526075","volume":"36","author":"R Lotti","year":"2025","unstructured":"Lotti R, Amato A, Bennett B, Zanocco-Marani T, Marconi A, Pincelli C. Treatment of pemphigus and other neglected skin conditions with PC111, a human anti-Fas Ligand monoclonal antibody: a potential disease modifier. J Dermatolog Treat. 2025;36:2526075. https:\/\/doi.org\/10.1080\/09546634.2025.2526075.","journal-title":"J Dermatolog Treat"},{"key":"9756_CR60","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1007\/s12640-016-9629-1","volume":"30","author":"D Milanovic","year":"2016","unstructured":"Milanovic D, Pesic V, Loncarevic-Vasiljkovic N, Pavkovic Z, Popic J, Kanazir S, et al. The Fas Ligand\/Fas Death Receptor Pathways Contribute to Propofol-Induced Apoptosis and Neuroinflammation in the Brain of Neonatal Rats. Neurotox Res. 2016;30:434\u201352. https:\/\/doi.org\/10.1007\/s12640-016-9629-1.","journal-title":"Neurotox Res"},{"key":"9756_CR61","doi-asserted-by":"publisher","first-page":"824","DOI":"10.2164\/jandrol.111.015529","volume":"33","author":"M Kuerban","year":"2012","unstructured":"Kuerban M, Naito M, Hirai S, Terayama H, Qu N, Musha M, et al. Involvement of Fas\/Fas-L and Bax\/Bcl-2 systems in germ cell death following immunization with syngeneic testicular germ cells in mice. J Androl. 2012;33:824\u201331. https:\/\/doi.org\/10.2164\/jandrol.111.015529.","journal-title":"J Androl"},{"key":"9756_CR62","first-page":"920","volume":"43","author":"H Chang","year":"2005","unstructured":"Chang H, Han B, Han X. [The mechanisms responsible for the therapeutic effects of anti-Fas ligand antibody on viral myocarditis in mice]. Zhonghua Er Ke Za Zhi Chin J Pediatr. 2005;43:920\u20134.","journal-title":"Zhonghua Er Ke Za Zhi Chin J Pediatr"},{"key":"9756_CR63","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.2337\/diabetes.51.5.1391","volume":"51","author":"M Nakayama","year":"2002","unstructured":"Nakayama M, Nagata M, Yasuda H, Arisawa K, Kotani R, Yamada K, et al. Fas\/Fas ligand interactions play an essential role in the initiation of murine autoimmune diabetes. Diabetes. 2002;51:1391\u20137. https:\/\/doi.org\/10.2337\/diabetes.51.5.1391.","journal-title":"Diabetes"},{"key":"9756_CR64","first-page":"6392","volume":"162","author":"BN Dittel","year":"1999","unstructured":"Dittel BN, Merchant RM, Janeway CA. Evidence for Fas-dependent and Fas-independent mechanisms in the pathogenesis of experimental autoimmune encephalomyelitis. J Immunol Baltim Md 1950. 1999;162:6392\u2013400.","journal-title":"J Immunol Baltim Md 1950"},{"key":"9756_CR65","doi-asserted-by":"publisher","unstructured":"Yolcu ES, Shirwan H, Askenasy N. Fas\/Fas-Ligand Interaction As a Mechanism of Immune Homeostasis and \u03b2-Cell Cytotoxicity: Enforcement Rather Than Neutralization for Treatment of Type 1 Diabetes. Front Immunol 2017;8. https:\/\/doi.org\/10.3389\/fimmu.2017.00342.","DOI":"10.3389\/fimmu.2017.00342"},{"key":"9756_CR66","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2019-000375","volume":"7","author":"FB Vincent","year":"2020","unstructured":"Vincent FB, Kandane-Rathnayake R, Koelmeyer R, Harris J, Hoi AY, Mackay F, et al. Associations of serum soluble Fas and Fas ligand (FasL) with outcomes in systemic lupus erythematosus. Lupus Sci Med. 2020;7:e000375. https:\/\/doi.org\/10.1136\/lupus-2019-000375.","journal-title":"Lupus Sci Med"},{"key":"9756_CR67","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1126\/science.7539157","volume":"268","author":"F Rieux-Laucat","year":"1995","unstructured":"Rieux-Laucat F, Le Deist F, Hivroz C, Roberts IAG, Debatin KM, Fischer A, et al. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science. 1995;268:1347\u20139. https:\/\/doi.org\/10.1126\/science.7539157.","journal-title":"Science"},{"key":"9756_CR68","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/S0022-3476(67)80262-2","volume":"70","author":"VC Canale","year":"1967","unstructured":"Canale VC, Smith CH. Chronic lymphadenopathy simulating malignant lymphoma. J Pediatr. 1967;70:891\u20139. https:\/\/doi.org\/10.1016\/S0022-3476(67)80262-2.","journal-title":"J Pediatr"},{"key":"9756_CR69","doi-asserted-by":"publisher","first-page":"e20192191","DOI":"10.1084\/jem.20192191","volume":"218","author":"ME Maccari","year":"2021","unstructured":"Maccari ME, Fuchs S, Kury P, Andrieux G, V\u00f6lkl S, Bengsch B, et al. A distinct CD38 + CD45RA+ population of CD4+, CD8+, and double-negative T cells is controlled by FAS. J Exp Med. 2021;218:e20192191. https:\/\/doi.org\/10.1084\/jem.20192191.","journal-title":"J Exp Med"},{"key":"9756_CR70","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-04-280347","volume":"116","author":"JB Oliveira","year":"2010","unstructured":"Oliveira JB, Bleesing JJ, Dianzani U, Fleisher TA, Jaffe ES, Lenardo MJ, et al. Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome (ALPS): report from the 2009 NIH international workshop. Blood. 2010;116:e35. https:\/\/doi.org\/10.1182\/blood-2010-04-280347.","journal-title":"Blood"},{"key":"9756_CR71","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1182\/blood.V89.4.1341","volume":"89","author":"MC Sneller","year":"1997","unstructured":"Sneller MC, Wang J, Dale JK, Strober W, Middelton LA, Choi Y, et al. Clincal, immunologic, and genetic features of an autoimmune lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis. Blood. 1997;89:1341\u20138.","journal-title":"Blood"},{"key":"9756_CR72","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1172\/JCI115867","volume":"90","author":"MC Sneller","year":"1992","unstructured":"Sneller MC, Straus SE, Jaffe ES, Jaffe JS, Fleisher TA, Stetler-Stevenson M, et al. A novel lymphoproliferative\/autoimmune syndrome resembling murine lpr\/gld disease. J Clin Invest. 1992;90:334\u201341. https:\/\/doi.org\/10.1172\/JCI115867.","journal-title":"J Clin Invest"},{"key":"9756_CR73","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1182\/blood-2015-11-685024","volume":"128","author":"S V\u00f6lkl","year":"2016","unstructured":"V\u00f6lkl S, Rensing-Ehl A, Allg\u00e4uer A, Schreiner E, Lorenz MR, Rohr J, et al. Hyperactive mTOR pathway promotes lymphoproliferation and abnormal differentiation in autoimmune lymphoproliferative syndrome. Blood. 2016;128:227\u201338. https:\/\/doi.org\/10.1182\/blood-2015-11-685024.","journal-title":"Blood"},{"key":"9756_CR74","doi-asserted-by":"publisher","first-page":"e35","DOI":"10.1182\/blood-2010-04-280347","volume":"116","author":"JB Oliveira","year":"2010","unstructured":"Oliveira JB, Bleesing JJ, Dianzani U, Fleisher TA, Jaffe ES, Lenardo MJ, et al. Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome (ALPS): report from the 2009 NIH International Workshop. Blood. 2010;116:e35\u201340. https:\/\/doi.org\/10.1182\/blood-2010-04-280347.","journal-title":"Blood"},{"key":"9756_CR75","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1097\/00002281-200307000-00008","volume":"15","author":"MC Sneller","year":"2003","unstructured":"Sneller MC, Dale JK, Straus SE. Autoimmune lymphoproliferative syndrome. Curr Opin Rheumatol. 2003;15:417\u201321. https:\/\/doi.org\/10.1097\/00002281-200307000-00008.","journal-title":"Curr Opin Rheumatol"},{"key":"9756_CR76","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.11545.1","volume":"6","author":"K Bride","year":"2017","unstructured":"Bride K, Teachey D. Autoimmune lymphoproliferative syndrome: more than a FAScinating disease. F1000Res. 2017;6:1928. https:\/\/doi.org\/10.12688\/f1000research.11545.1.","journal-title":"F1000Res"},{"key":"9756_CR77","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s00277-022-04761-7","volume":"101","author":"F Consonni","year":"2022","unstructured":"Consonni F, Gambineri E, Favre C. ALPS, FAS, and beyond: from inborn errors of immunity to acquired immunodeficiencies. Ann Hematol. 2022;101:469\u201384. https:\/\/doi.org\/10.1007\/s00277-022-04761-7.","journal-title":"Ann Hematol"},{"key":"9756_CR78","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.3324\/haematol.2014.114967","volume":"100","author":"S Nabhani","year":"2015","unstructured":"Nabhani S, Ginzel S, Miskin H, Revel-Vilk S, Harlev D, Fleckenstein B, et al. Deregulation of Fas ligand expression as a novel cause of autoimmune lymphoproliferative syndrome-like disease. Haematologica. 2015;100:1189\u201398. https:\/\/doi.org\/10.3324\/haematol.2014.114967.","journal-title":"Haematologica"},{"key":"9756_CR79","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000845","volume":"7","author":"E Palmisani","year":"2023","unstructured":"Palmisani E, Miano M, Grossi A, Lanciotti M, Lupia M, Terranova P, et al. Autoimmune Lymphoproliferative Syndrome (ALPS) disease and ALPS phenotype: are they two distinct entities? HemaSphere. 2023;7:e845. https:\/\/doi.org\/10.1097\/HS9.0000000000000845.","journal-title":"HemaSphere"},{"key":"9756_CR80","doi-asserted-by":"publisher","DOI":"10.1002\/eji.202451008","volume":"54","author":"EH Kim","year":"2024","unstructured":"Kim EH, Teerdhala SV, Padilla MS, Joseph RA, Li JJ, Haley RM, et al. Lipid nanoparticle-mediated RNA delivery for immune cell modulation. Eur J Immunol. 2024;54:2451008. https:\/\/doi.org\/10.1002\/eji.202451008.","journal-title":"Eur J Immunol"},{"key":"9756_CR81","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2024.115448","volume":"214","author":"E Garbayo","year":"2024","unstructured":"Garbayo E, El Moukhtari SH, Rodr\u00edguez-Nogales C, Agirre X, Rodriguez-Madoz JR, Rodriguez-Marquez P, et al. RNA-loaded nanoparticles for the treatment of hematological cancers. Adv Drug Deliv Rev. 2024;214:115448. https:\/\/doi.org\/10.1016\/j.addr.2024.115448.","journal-title":"Adv Drug Deliv Rev"},{"key":"9756_CR82","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/nbt0797-647","volume":"15","author":"NS Templeton","year":"1997","unstructured":"Templeton NS, Lasic DD, Frederik PM, Strey HH, Roberts DD, Pavlakis GN. Improved DNA: liposome complexes for increased systemic delivery and gene expression. Nat Biotechnol. 1997;15:647\u201352. https:\/\/doi.org\/10.1038\/nbt0797-647.","journal-title":"Nat Biotechnol"},{"key":"9756_CR83","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14020361","volume":"14","author":"AD Merting","year":"2022","unstructured":"Merting AD, Poschel DB, Lu C, Klement JD, Yang D, Li H, et al. Restoring FAS expression via lipid-encapsulated FAS DNA nanoparticle delivery is sufficient to suppress colon tumor growth in vivo. Cancers. 2022;14:361. https:\/\/doi.org\/10.3390\/cancers14020361.","journal-title":"Cancers"},{"key":"9756_CR84","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1182\/blood.2022019333","volume":"142","author":"V Vavassori","year":"2023","unstructured":"Vavassori V, Ferrari S, Beretta S, Asperti C, Albano L, Annoni A, et al. Lipid nanoparticles allow efficient and harmless ex vivo gene editing of human hematopoietic cells. Blood. 2023;142:812\u201326. https:\/\/doi.org\/10.1182\/blood.2022019333.","journal-title":"Blood"},{"issue":"2","key":"9756_CR85","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1158\/2326-6066.CIR-17-0273","volume":"6","author":"IM Meraz","year":"2018","unstructured":"Meraz IM, Majidi M, Cao X, Lin H, Li L, Wang J, et al. TUSC2 immunogene therapy synergizes with anti\u2013PD-1 through enhanced proliferation and infiltration of natural killer cells in syngeneic Kras -mutant mouse lung cancer models. Cancer Immunol Res. 2018;6(2):163\u201377. https:\/\/doi.org\/10.1158\/2326-6066.CIR-17-0273.","journal-title":"Cancer Immunol Res"},{"key":"9756_CR86","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1158\/2159-8290.CD-11-0214","volume":"1","author":"RA Juergens","year":"2011","unstructured":"Juergens RA, Wrangle J, Vendetti FP, Murphy SC, Zhao M, Coleman B, et al. Combination epigenetic therapy has efficacy in patients with refractory advanced non\u2013small cell lung cancer. Cancer Discov. 2011;1:598\u2013607. https:\/\/doi.org\/10.1158\/2159-8290.CD-11-0214.","journal-title":"Cancer Discov"},{"key":"9756_CR87","doi-asserted-by":"publisher","first-page":"12695","DOI":"10.1021\/acsnano.2c04420","volume":"16","author":"ZY Al Subeh","year":"2022","unstructured":"Al Subeh ZY, Poschel DB, Redd PS, Klement JD, Merting AD, Yang D, et al. Lipid nanoparticle delivery of Fas plasmid restores Fas expression to suppress melanoma growth in vivo. ACS Nano. 2022;16:12695\u2013710. https:\/\/doi.org\/10.1021\/acsnano.2c04420.","journal-title":"ACS Nano"},{"key":"9756_CR88","doi-asserted-by":"publisher","DOI":"10.1016\/j.bict.2025.100010","volume":"1","author":"DB Poschel","year":"2025","unstructured":"Poschel DB, Tiamiyu Z, Redd P, Merting A, Savage N, Liu K. Lipid nanoparticle Fas gene therapy suppresses autoimmune lymphoproliferative syndrome in mice. Blood Immunol Cell Ther. 2025;1:100010. https:\/\/doi.org\/10.1016\/j.bict.2025.100010.","journal-title":"Blood Immunol Cell Ther"},{"key":"9756_CR89","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/nm0497-409","volume":"3","author":"T Kondo","year":"1997","unstructured":"Kondo T, Suda T, Fukuyama H, Adachi M, Nagata S. Essential roles of the Fas ligand in the development of hepatitis. Nat Med. 1997;3:409\u201313. https:\/\/doi.org\/10.1038\/nm0497-409.","journal-title":"Nat Med"},{"key":"9756_CR90","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.cyto.2014.10.004","volume":"75","author":"F Calmon-Hamaty","year":"2015","unstructured":"Calmon-Hamaty F, Audo R, Combe B, Morel J, Hahne M. Targeting the Fas\/FasL system in Rheumatoid Arthritis therapy: Promising or risky? Cytokine. 2015;75:228\u201333. https:\/\/doi.org\/10.1016\/j.cyto.2014.10.004.","journal-title":"Cytokine"},{"key":"9756_CR91","doi-asserted-by":"publisher","first-page":"3845","DOI":"10.3390\/jcm9123845","volume":"9","author":"J Sremec","year":"2020","unstructured":"Sremec J, Tomasovi\u0107 S, Tomi\u0107 Sremec N, \u0160u\u0107ur A, Ko\u0161\u0107ak Luka\u010d J, Ba\u010di\u0107 Baronica K, et al. Elevated Concentrations of Soluble Fas and FasL in Multiple Sclerosis Patients with Antinuclear Antibodies. J Clin Med. 2020;9:3845. https:\/\/doi.org\/10.3390\/jcm9123845.","journal-title":"J Clin Med"},{"key":"9756_CR92","doi-asserted-by":"publisher","unstructured":"Department of Molecular Medicine, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey, Demir A, Kahraman R, Department of Gastroenterology, Umraniye Training and Research Hospital, Istanbul, Turkey, Candan G, Department of Molecular Medicine, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey, et al. The role of FAS gene variants in inflammatory bowel disease. Turk J Gastroenterol 2020;31:356\u201361. https:\/\/doi.org\/10.5152\/tjg.2020.19436.","DOI":"10.5152\/tjg.2020.19436"},{"key":"9756_CR93","doi-asserted-by":"publisher","first-page":"1029737","DOI":"10.3389\/fimmu.2022.1029737","volume":"13","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Jin T, Dou Z, Wei B, Zhang B, Sun C. The dual role of the CD95 and CD95L signaling pathway in glioblastoma. Front Immunol. 2022;13:1029737. https:\/\/doi.org\/10.3389\/fimmu.2022.1029737.","journal-title":"Front Immunol"},{"key":"9756_CR94","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/s41422-019-0164-5","volume":"29","author":"D Tang","year":"2019","unstructured":"Tang D, Kang R, Berghe TV, Vandenabeele P, Kroemer G. The molecular machinery of regulated cell death. Cell Res. 2019;29:347\u201364. https:\/\/doi.org\/10.1038\/s41422-019-0164-5.","journal-title":"Cell Res"},{"key":"9756_CR95","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S0092-8674(02)00625-6","volume":"108","author":"RW Johnstone","year":"2002","unstructured":"Johnstone RW, Ruefli AA, Lowe SW. Apoptosis Cell. 2002;108:153\u201364. https:\/\/doi.org\/10.1016\/S0092-8674(02)00625-6.","journal-title":"Apoptosis. Cell"},{"key":"9756_CR96","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1074\/jbc.M509866200","volume":"281","author":"VN Ivanov","year":"2006","unstructured":"Ivanov VN, Ronai Z, Hei TK. Opposite Roles of FAP-1 and Dynamin in the Regulation of Fas (CD95) Translocation to the Cell Surface and Susceptibility to Fas Ligand-mediated Apoptosis. J Biol Chem. 2006;281:1840\u201352. https:\/\/doi.org\/10.1074\/jbc.M509866200.","journal-title":"J Biol Chem"},{"key":"9756_CR97","doi-asserted-by":"crossref","unstructured":"Park WS, Oh RR, Kim YS, Park JY, Lee SH, Shin MS, et al. Somatic mutations in the death domain of the Fas (Apo-1\/CD95) gene in gastric cancer. J Pathol. 2001;193:162\u20138. https:\/\/doi.org\/10.1002\/1096-9896(2000)9999:9999%253C::aid-path759%253E3.0.co;2-a.","DOI":"10.1002\/1096-9896(2000)9999:9999<::AID-PATH759>3.0.CO;2-A"},{"key":"9756_CR98","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.3748\/wjg.v9.i7.1415","volume":"9","author":"H-C Zheng","year":"2003","unstructured":"Zheng H-C. Expression of Fas ligand and Caspase-3 contributes to formation of immune escape in gastric cancer. World J Gastroenterol. 2003;9:1415. https:\/\/doi.org\/10.3748\/wjg.v9.i7.1415.","journal-title":"World J Gastroenterol"},{"issue":"160","key":"9756_CR99","first-page":"5669","volume":"1998","author":"MW Bennett","year":"1950","unstructured":"Bennett MW, O\u2019Connell J, O\u2019Sullivan GC, Brady C, Roche D, Collins JK, et al. The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J Immunol Baltim Md. 1950;1998(160):5669\u201375.","journal-title":"J Immunol Baltim Md"},{"key":"9756_CR100","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1126\/science.274.5291.1363","volume":"274","author":"M Hahne","year":"1996","unstructured":"Hahne M, Rimoldi D, Schr\u00f6ter M, Romero P, Schreier M, French LE, et al. Melanoma Cell Expression of Fas(Apo-1\/CD95) Ligand: Implications for Tumor Immune Escape. Science. 1996;274:1363\u20136. https:\/\/doi.org\/10.1126\/science.274.5291.1363.","journal-title":"Science"},{"key":"9756_CR101","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1111\/j.1749-6632.2000.tb06708.x","volume":"910","author":"J O\u2019Connell","year":"2000","unstructured":"O\u2019Connell J, Bennett MW, Nally K, Houston A, O\u2019Sullivan GC, Shanahan F. Altered mechanisms of apoptosis in colon cancer: Fas resistance and counterattack in the tumor-immune conflict. Ann N Y Acad Sci. 2000;910:178\u201395. https:\/\/doi.org\/10.1111\/j.1749-6632.2000.tb06708.x.","journal-title":"Ann N Y Acad Sci"},{"key":"9756_CR102","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0014527","volume":"6","author":"C Menke","year":"2011","unstructured":"Menke C, Goncharov T, Qamar L, Korch C, Ford HL, Behbakht K, et al. TRAIL receptor signaling regulation of chemosensitivity in vivo but not in vitro. PLoS One. 2011;6:e14527. https:\/\/doi.org\/10.1371\/journal.pone.0014527.","journal-title":"PLoS One"},{"key":"9756_CR103","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1084\/jem.191.7.1209","volume":"191","author":"AM Hohlbaum","year":"2000","unstructured":"Hohlbaum AM, Moe S, Marshak-Rothstein A. Opposing effects of transmembrane and soluble Fas ligand expression on inflammation and tumor cell survival. J Exp Med. 2000;191:1209\u201320. https:\/\/doi.org\/10.1084\/jem.191.7.1209.","journal-title":"J Exp Med"},{"key":"9756_CR104","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1136\/gut.2004.052696","volume":"54","author":"J Strater","year":"2005","unstructured":"Strater J. Impaired CD95 expression predisposes for recurrence in curatively resected colon carcinoma: clinical evidence for immunoselection and CD95L mediated control of minimal residual disease. Gut. 2005;54:661\u20135. https:\/\/doi.org\/10.1136\/gut.2004.052696.","journal-title":"Gut"},{"key":"9756_CR105","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1053\/j.gastro.2009.06.004","volume":"137","author":"H Li","year":"2009","unstructured":"Li H, Fan X, Stoicov C, Liu JH, Zubair S, Tsai E, et al. Human and mouse colon cancer utilizes CD95 signaling for local growth and metastatic spread to liver. Gastroenterology. 2009;137:934\u2013944.e4. https:\/\/doi.org\/10.1053\/j.gastro.2009.06.004.","journal-title":"Gastroenterology"},{"key":"9756_CR106","first-page":"4507","volume":"31","author":"FJH Hoogwater","year":"2011","unstructured":"Hoogwater FJH, Snoeren N, Nijkamp MW, Gunning AC, Van Houdt WJ, De Bruijn MT, et al. Circulating CD95-ligand as a potential prognostic marker for recurrence in patients with synchronous colorectal liver metastases. Anticancer Res. 2011;31:4507\u201312.","journal-title":"Anticancer Res"},{"key":"9756_CR107","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.bbcan.2012.03.007","volume":"1826","author":"FJH Hoogwater","year":"2012","unstructured":"Hoogwater FJH, Steller EJA, Westendorp BF, Borel Rinkes IHM, Kranenburg O. CD95 signaling in colorectal cancer. Biochim Biophys Acta BBA-Rev Cancer. 2012;1826:189\u201398. https:\/\/doi.org\/10.1016\/j.bbcan.2012.03.007.","journal-title":"Biochim Biophys Acta BBA-Rev Cancer"},{"key":"9756_CR108","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1038\/nm0596-574","volume":"2","author":"C Friesen","year":"1996","unstructured":"Friesen C, Herr I, Krammer PH, Debatin K-M. Involvement of the CD95 (APO\u20131\/Fas) receptor\/ligand system in drug\u2013induced apoptosis in leukemia cells. Nat Med. 1996;2:574\u20137. https:\/\/doi.org\/10.1038\/nm0596-574.","journal-title":"Nat Med"},{"key":"9756_CR109","first-page":"685","volume":"9","author":"M M\u00fcller","year":"1998","unstructured":"M\u00fcller M, Scaffidi CA, Galle PR, Stremmel W, Krammer PH. The role of p53 and the CD95 (APO-1\/Fas) death system in chemotherapy-induced apoptosis. Eur Cytokine Netw. 1998;9:685\u20136.","journal-title":"Eur Cytokine Netw"},{"key":"9756_CR110","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1038\/sj.cdd.4400419","volume":"5","author":"S Fulda","year":"1998","unstructured":"Fulda S, Scaffidi C, Pietsch T, Krammer PH, Peter ME, Debatin K-M. Activation of the CD95 (APO-1\/Fas) pathway in drug- and \u03b3-irradiation-induced apoptosis of brain tumor cells. Cell Death Differ. 1998;5:884\u201393. https:\/\/doi.org\/10.1038\/sj.cdd.4400419.","journal-title":"Cell Death Differ"},{"key":"9756_CR111","doi-asserted-by":"publisher","first-page":"77","DOI":"10.4103\/ijmr.IJMR_2058_19","volume":"156","author":"R Asgari","year":"2022","unstructured":"Asgari R, Bidmeshkipour A, Mansouri K, Bakhtiari M, Mozafari H, Abdolmaleki A. Fas cell surface death receptor\/Fas ligand genetic variants in gastric cancer patients: a case-control study. Indian J Med Res. 2022;156:77\u201382. https:\/\/doi.org\/10.4103\/ijmr.IJMR_2058_19.","journal-title":"Indian J Med Res"},{"key":"9756_CR112","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1038\/cdd.2014.217","volume":"22","author":"M Teodorczyk","year":"2015","unstructured":"Teodorczyk M, Kleber S, Wollny D, Sefrin JP, Aykut B, Mateos A, et al. CD95 promotes metastatic spread via Sck in pancreatic ductal adenocarcinoma. Cell Death Differ. 2015;22:1192\u2013202. https:\/\/doi.org\/10.1038\/cdd.2014.217.","journal-title":"Cell Death Differ"},{"key":"9756_CR113","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1002\/cncr.27937","volume":"119","author":"TK Owonikoko","year":"2013","unstructured":"Owonikoko TK, Hossain MS, Bhimani C, Chen Z, Kim S, Ramalingam SS, et al. Soluble FAS ligand as a biomarker of disease recurrence in differentiated thyroid cancer. Cancer. 2013;119:1503\u201311. https:\/\/doi.org\/10.1002\/cncr.27937.","journal-title":"Cancer"},{"key":"9756_CR114","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1182\/blood-2011-04-349803","volume":"119","author":"NJ Sunter","year":"2012","unstructured":"Sunter NJ, Scott K, Hills R, Grimwade D, Taylor S, Worrillow LJ, et al. A functional variant in the core promoter of the CD95 cell death receptor gene predicts prognosis in acute promyelocytic leukemia. Blood. 2012;119:196\u2013205. https:\/\/doi.org\/10.1182\/blood-2011-04-349803.","journal-title":"Blood"},{"key":"9756_CR115","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1159\/000334453","volume":"88","author":"T Sejima","year":"2012","unstructured":"Sejima T, Morizane S, Hinata N, Yao A, Isoyama T, Saito M, et al. Fas Expression in Renal Cell Carcinoma Accurately Predicts Patient Survival after Radical Nephrectomy. Urol Int. 2012;88:263\u201370. https:\/\/doi.org\/10.1159\/000334453.","journal-title":"Urol Int"},{"key":"9756_CR116","first-page":"130","volume":"10","author":"AEI El Bassiouny","year":"2008","unstructured":"El Bassiouny AEI, El-Bassiouni NEI, Nosseir MMF, Zoheiry MMK, El-Ahwany EG, Salah F, et al. Circulating and hepatic Fas expression in HCV-induced chronic liver disease and hepatocellular carcinoma. Medscape J Med. 2008;10:130.","journal-title":"Medscape J Med"},{"key":"9756_CR117","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1172\/JCI119273","volume":"99","author":"P Saas","year":"1997","unstructured":"Saas P, Walker PR, Hahne M, Quiquerez AL, Schnuriger V, Perrin G, et al. Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain? J Clin Invest. 1997;99:1173\u20138. https:\/\/doi.org\/10.1172\/JCI119273.","journal-title":"J Clin Invest"},{"key":"9756_CR118","doi-asserted-by":"publisher","first-page":"3943","DOI":"10.1073\/pnas.94.8.3943","volume":"94","author":"J Allison","year":"1997","unstructured":"Allison J, Georgiou HM, Strasser A, Vaux DL. Transgenic expression of CD95 ligand on islet \u03b2 cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts. Proc Natl Acad Sci USA. 1997;94:3943\u20137. https:\/\/doi.org\/10.1073\/pnas.94.8.3943.","journal-title":"Proc Natl Acad Sci USA"},{"key":"9756_CR119","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1038\/nm0797-738","volume":"3","author":"S-M Kang","year":"1997","unstructured":"Kang S-M, Schneider DB, Lin Z, Hanahan D, Dichek DA, Stock PG, et al. Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nat Med. 1997;3:738\u201343. https:\/\/doi.org\/10.1038\/nm0797-738.","journal-title":"Nat Med"},{"key":"9756_CR120","first-page":"59","volume":"59","author":"DB Chappell","year":"1999","unstructured":"Chappell DB, Zaks TZ, Rosenberg SA, Restifo NP. Human melanoma cells do not express Fas (Apo-1\/CD95) ligand. Cancer Res. 1999;59:59\u201362.","journal-title":"Cancer Res"},{"key":"9756_CR121","doi-asserted-by":"publisher","first-page":"5480","DOI":"10.4049\/jimmunol.165.10.5480","volume":"165","author":"JL Wahlsten","year":"2000","unstructured":"Wahlsten JL, Gitchell HL, Chan C-C, Wiggert B, Caspi RR. Fas and Fas ligand expressed on cells of the immune system, not on the target tissue, control induction of experimental autoimmune uveitis. J Immunol. 2000;165:5480\u20136. https:\/\/doi.org\/10.4049\/jimmunol.165.10.5480.","journal-title":"J Immunol"},{"key":"9756_CR122","doi-asserted-by":"publisher","first-page":"591","DOI":"10.7326\/0003-4819-130-7-199904060-00020","volume":"130","author":"SE Straus","year":"1999","unstructured":"Straus SE, Sneller M, Lenardo MJ, Puck JM, Strober W. An inherited disorder of lymphocyte apoptosis: the autoimmune lymphoproliferative syndrome. Ann Intern Med. 1999;130:591\u2013601. https:\/\/doi.org\/10.7326\/0003-4819-130-7-199904060-00020.","journal-title":"Ann Intern Med"},{"key":"9756_CR123","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/74955","volume":"6","author":"NP Restifo","year":"2000","unstructured":"Restifo NP. Not so Fas: re-evaluating the mechanisms of immune privilege and tumor escape. Nat Med. 2000;6:493\u20135. https:\/\/doi.org\/10.1038\/74955.","journal-title":"Nat Med"},{"key":"9756_CR124","doi-asserted-by":"publisher","DOI":"10.1038\/85357","volume":"7","author":"NP Restifo","year":"2001","unstructured":"Restifo NP. Countering the \u201ccounterattack\u201d hypothesis. Nat Med. 2001;7:259. https:\/\/doi.org\/10.1038\/85357.","journal-title":"Nat Med"},{"key":"9756_CR125","doi-asserted-by":"publisher","first-page":"527","DOI":"10.3109\/08830189909088497","volume":"18","author":"OM Martinez","year":"1999","unstructured":"Martinez OM, Krams SM. Involvement of Fas-Fas ligand interactions in graft rejection. Int Rev Immunol. 1999;18:527\u201346. https:\/\/doi.org\/10.3109\/08830189909088497.","journal-title":"Int Rev Immunol"},{"key":"9756_CR126","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S0952-7915(96)80062-8","volume":"8","author":"AM Kruisbeek","year":"1996","unstructured":"Kruisbeek AM, Amsen D. Mechanisms underlying T-cell tolerance. Curr Opin Immunol. 1996;8:233\u201344. https:\/\/doi.org\/10.1016\/S0952-7915(96)80062-8.","journal-title":"Curr Opin Immunol"},{"key":"9756_CR127","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01377-9","volume":"8","author":"Q Li","year":"2023","unstructured":"Li Q, Lan P. Activation of immune signals during organ transplantation. Signal Transduct Target Ther. 2023;8:110. https:\/\/doi.org\/10.1038\/s41392-023-01377-9.","journal-title":"Signal Transduct Target Ther"},{"key":"9756_CR128","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.trre.2011.09.002","volume":"26","author":"B Priyadharshini","year":"2012","unstructured":"Priyadharshini B, Greiner DL, Brehm MA. T-cell activation and transplantation tolerance. Transplant Rev. 2012;26:212\u201322. https:\/\/doi.org\/10.1016\/j.trre.2011.09.002.","journal-title":"Transplant Rev"},{"key":"9756_CR129","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1097\/01.tp.0000168432.60022.99","volume":"80","author":"MR Clarkson","year":"2005","unstructured":"Clarkson MR, Sayegh MH. T-cell costimulatory pathways in allograft rejection and tolerance. Transplantation. 2005;80:555\u201363. https:\/\/doi.org\/10.1097\/01.tp.0000168432.60022.99.","journal-title":"Transplantation"},{"key":"9756_CR130","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.4049\/jimmunol.176.3.1561","volume":"176","author":"TB Thornley","year":"2006","unstructured":"Thornley TB, Brehm MA, Markees TG, Shultz LD, Mordes JP, Welsh RM, et al. TLR agonists abrogate costimulation blockade-induced prolongation of skin allografts. J Immunol. 2006;176:1561\u201370. https:\/\/doi.org\/10.4049\/jimmunol.176.3.1561.","journal-title":"J Immunol"},{"key":"9756_CR131","doi-asserted-by":"publisher","first-page":"512","DOI":"10.4049\/jimmunol.164.1.512","volume":"164","author":"NN Iwakoshi","year":"2000","unstructured":"Iwakoshi NN, Mordes JP, Markees TG, Phillips NE, Rossini AA, Greiner DL. Treatment of allograft recipients with donor-specific transfusion and anti-CD154 antibody leads to deletion of alloreactive CD8\u2009+\u2009T cells and prolonged graft survival in a CTLA4-dependent manner. J Immunol. 2000;164:512\u201321. https:\/\/doi.org\/10.4049\/jimmunol.164.1.512.","journal-title":"J Immunol"},{"key":"9756_CR132","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1038\/15260","volume":"5","author":"AD Wells","year":"1999","unstructured":"Wells AD, Li XC, Li Y, Walsh MC, Zheng XX, Wu Z, et al. Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance. Nat Med. 1999;5:1303\u20137. https:\/\/doi.org\/10.1038\/15260.","journal-title":"Nat Med"},{"key":"9756_CR133","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/83253","volume":"7","author":"XC Li","year":"2001","unstructured":"Li XC, Demirci G, Ferrari-Lacraz S, Groves C, Coyle A, Malek TR, et al. IL-15 and IL-2: a matter of life and death for T cells in vivo. Nat Med. 2001;7:114\u20138. https:\/\/doi.org\/10.1038\/83253.","journal-title":"Nat Med"},{"key":"9756_CR134","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1097\/01.TP.0000089242.86443.40","volume":"76","author":"L Xie","year":"2003","unstructured":"Xie L, Shi W, Guo P. Roles of tumor necrosis factor-related apoptosis-inducing ligand in corneal transplantation. Transplantation. 2003;76:1556\u20139. https:\/\/doi.org\/10.1097\/01.TP.0000089242.86443.40.","journal-title":"Transplantation"},{"key":"9756_CR135","doi-asserted-by":"publisher","unstructured":"Ferguson TA, Griffith TS. The Role of Fas Ligand and TNF-Related Apoptosis-Inducing Ligand (TRAIL) in the Ocular Immune Response. In: Niederkorn JY, Kaplan HJ, editors. Chem. Immunol. Allergy, Basel: KARGER; 2007;140\u201354. https:\/\/doi.org\/10.1159\/000099265.","DOI":"10.1159\/000099265"},{"key":"9756_CR136","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1038\/nri2570","volume":"9","author":"P Bouillet","year":"2009","unstructured":"Bouillet P, O\u2019Reilly LA. CD95, BIM and T cell homeostasis. Nat Rev Immunol. 2009;9:514\u20139. https:\/\/doi.org\/10.1038\/nri2570.","journal-title":"Nat Rev Immunol"},{"key":"9756_CR137","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1097\/00007890-199710270-00004","volume":"64","author":"S Yamagami","year":"1997","unstructured":"Yamagami S, Kawashima H, Tsuru T, Yamagami H, Kayagaki N, Yagita H, et al. ROLE OF FAS-FAS LIGAND INTERACTIONS IN THE IMMUNOREJECTION OF ALLOGENEIC MOUSE CORNEAL TRANSPLANTS1. Transplantation. 1997;64:1107\u201311. https:\/\/doi.org\/10.1097\/00007890-199710270-00004.","journal-title":"Transplantation"},{"key":"9756_CR138","doi-asserted-by":"publisher","first-page":"3615","DOI":"10.4049\/jimmunol.177.6.3615","volume":"177","author":"D Tokita","year":"2006","unstructured":"Tokita D, Shishida M, Ohdan H, Onoe T, Hara H, Tanaka Y, et al. Liver sinusoidal endothelial cells that endocytose allogeneic cells suppress T cells with indirect allospecificity. J Immunol. 2006;177:3615\u201324. https:\/\/doi.org\/10.4049\/jimmunol.177.6.3615.","journal-title":"J Immunol"},{"key":"9756_CR139","doi-asserted-by":"publisher","first-page":"920","DOI":"10.3390\/v3060920","volume":"3","author":"MR Thompson","year":"2011","unstructured":"Thompson MR, Kaminski JJ, Kurt-Jones EA, Fitzgerald KA. Pattern recognition receptors and the innate immune response to viral infection. Viruses. 2011;3:920\u201340. https:\/\/doi.org\/10.3390\/v3060920.","journal-title":"Viruses"},{"key":"9756_CR140","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1111\/imm.12044","volume":"138","author":"B Priyadharshini","year":"2013","unstructured":"Priyadharshini B, Thornley TB, Daniels KA, Cuthbert A, Welsh RM, Greiner DL, et al. Alloreactive CD8 T cells rescued from apoptosis during co-stimulation blockade by Toll-like receptor stimulation remain susceptible to Fas-induced cell death. Immunology. 2013;138:322\u201332. https:\/\/doi.org\/10.1111\/imm.12044.","journal-title":"Immunology"},{"key":"9756_CR141","doi-asserted-by":"publisher","first-page":"771","DOI":"10.4049\/jimmunol.175.2.771","volume":"175","author":"SA Quezada","year":"2005","unstructured":"Quezada SA, Bennett K, Blazar BR, Rudensky AY, Sakaguchi S, Noelle RJ. Analysis of the underlying cellular mechanisms of anti-CD154-induced graft tolerance: the interplay of clonal anergy and immune regulation. J Immunol. 2005;175:771\u20139. https:\/\/doi.org\/10.4049\/jimmunol.175.2.771.","journal-title":"J Immunol"},{"key":"9756_CR142","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1111\/j.1600-6143.2011.03879.x","volume":"12","author":"BE Burrell","year":"2012","unstructured":"Burrell BE, Bromberg JS. Fates of CD4\u2009+\u2009T cells in a tolerant environment depend on timing and place of antigen exposure. Am J Transplant. 2012;12:576\u201389. https:\/\/doi.org\/10.1111\/j.1600-6143.2011.03879.x.","journal-title":"Am J Transplant"},{"key":"9756_CR143","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1615\/CritRevImmunol.v28.i5.30","volume":"28","author":"DM Miller","year":"2008","unstructured":"Miller DM, Rossini AA, Greiner DL. Role of innate immunity in transplantation tolerance. Crit Rev Immunol. 2008;28:403\u201339. https:\/\/doi.org\/10.1615\/CritRevImmunol.v28.i5.30.","journal-title":"Crit Rev Immunol"},{"key":"9756_CR144","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1097\/00007890-200111270-00025","volume":"72","author":"N Shulzhenko","year":"2001","unstructured":"Shulzhenko N, Morgun A, Zheng XX, Diniz RVZ, Almeida DR, Ma N, et al. Intragraft activation of genes encoding cytotoxic T lymphocyte effector molecules precedes the histological evidence of rejection in human cardiac transplantation1. Transplantation. 2001;72:1705\u20138. https:\/\/doi.org\/10.1097\/00007890-200111270-00025.","journal-title":"Transplantation"},{"key":"9756_CR145","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1097\/00007890-200104150-00015","volume":"71","author":"S-I Oh","year":"2001","unstructured":"Oh S-I, Kim I-W, Jung H-C, Seo J-W, Chae I-H, Kim H-S, et al. Correlation of Fas and Fas ligand expression with rejection status of transplanted heart in human1. Transplantation. 2001;71:906\u20139. https:\/\/doi.org\/10.1097\/00007890-200104150-00015.","journal-title":"Transplantation"},{"key":"9756_CR146","first-page":"921","volume":"74","author":"C Dong","year":"1996","unstructured":"Dong C, Wilson JE, Winters GL, McManus BM. Human transplant coronary artery disease: pathological evidence for Fas-mediated apoptotic cytotoxicity in allograft arteriopathy. Lab Investig J Tech Methods Pathol. 1996;74:921\u201331.","journal-title":"Lab Investig J Tech Methods Pathol"},{"key":"9756_CR147","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1093\/intimm\/8.9.1347","volume":"8","author":"K Seino","year":"1996","unstructured":"Seino K, Kayagaki N, Bashuda H, Okumura K, Yagita H, Hamaoka T. Contribution of Fas ligand to cardiac allograft rejection. Int Immunol. 1996;8:1347\u201354. https:\/\/doi.org\/10.1093\/intimm\/8.9.1347.","journal-title":"Int Immunol"},{"key":"9756_CR148","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.humimm.2006.02.037","volume":"67","author":"EC P\u00e9rez","year":"2006","unstructured":"P\u00e9rez EC, Shulzhenko N, Morgun A, Diniz RVZ, Almeida DR, Musatti CC, et al. Expression of Fas, FasL, and soluble Fas mRNA in endomyocardial biopsies of human cardiac allografts. Hum Immunol. 2006;67:22\u20136. https:\/\/doi.org\/10.1016\/j.humimm.2006.02.037.","journal-title":"Hum Immunol"},{"key":"9756_CR149","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1681\/ASN.V1171266","volume":"11","author":"C Lorz","year":"2000","unstructured":"Lorz C, Ortiz A, Justo P, Gonz\u00e1lez-Cuadrado S, Duque N, G\u00f3mez-Guerrero C, et al. Proapoptotic Fas ligand is expressed by normal kidney tubular epithelium and injured glomeruli. J Am Soc Nephrol. 2000;11:1266\u201377. https:\/\/doi.org\/10.1681\/ASN.V1171266.","journal-title":"J Am Soc Nephrol"},{"key":"9756_CR150","doi-asserted-by":"publisher","first-page":"F1193","DOI":"10.1152\/ajprenal.1996.271.6.F1193","volume":"271","author":"A Ortiz-Arduan","year":"1996","unstructured":"Ortiz-Arduan A, Danoff TM, Kalluri R, Gonzalez-Cuadrado S, Karp SL, Elkon K, et al. Regulation of Fas and Fas ligand expression in cultured murine renal cells and in the kidney during endotoxemia. Am J Physiol-Ren Physiol. 1996;271:F1193\u2013201. https:\/\/doi.org\/10.1152\/ajprenal.1996.271.6.F1193.","journal-title":"Am J Physiol-Ren Physiol"},{"key":"9756_CR151","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1097\/00007890-200003270-00012","volume":"69","author":"CJ Porter","year":"2000","unstructured":"Porter CJ, Ronan JE, Cassidy MJD. FAS-FAS-LIGAND antigen expression and its relationship to increased apoptosis in acute renal transplant rejection1. Transplantation. 2000;69:1091\u20134. https:\/\/doi.org\/10.1097\/00007890-200003270-00012.","journal-title":"Transplantation"},{"key":"9756_CR152","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1681\/ASN.V8101517","volume":"8","author":"JG Boonstra","year":"1997","unstructured":"Boonstra JG, Van Der Woude FJ, Wever PC, Laterveer JC, Daha MR, Van Kooten C. Expression and function of Fas (CD95) on human renal tubular epithelial cells. J Am Soc Nephrol. 1997;8:1517\u201324. https:\/\/doi.org\/10.1681\/ASN.V8101517.","journal-title":"J Am Soc Nephrol"},{"key":"9756_CR153","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1097\/00007890-199807270-00021","volume":"66","author":"PC Wever","year":"1998","unstructured":"Wever PC, Boonstra JG, Laterveer JC, Hack EC, Van Der Woude FJ, Daha MR, et al. Mechanisms of lymphocyte-mediated cytotoxicity in acute renal allograft rejection1. Transplantation. 1998;66:259\u201364. https:\/\/doi.org\/10.1097\/00007890-199807270-00021.","journal-title":"Transplantation"},{"key":"9756_CR154","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/S0168-8278(97)80418-7","volume":"26","author":"C Gapany","year":"1997","unstructured":"Gapany C, Ming Z, Arthur Z. The apoptosis protector, bcl-2 protein, is downregulated in bile duct epithelial cells of human liver allografts. J Hepatol. 1997;26:535\u201342. https:\/\/doi.org\/10.1016\/S0168-8278(97)80418-7.","journal-title":"J Hepatol"},{"key":"9756_CR155","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1046\/j.1365-2249.1999.01035.x","volume":"118","author":"TL Pan","year":"1999","unstructured":"Pan TL, Goto S, Lin YC, Lord R, Chiang KC, Lai CY, et al. The fas and fas ligand pathways in liver allograft tolerance. Clin Exp Immunol. 1999;118:180\u20137. https:\/\/doi.org\/10.1046\/j.1365-2249.1999.01035.x.","journal-title":"Clin Exp Immunol"},{"key":"9756_CR156","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/nm0198-031","volume":"4","author":"M Tanaka","year":"1998","unstructured":"Tanaka M, Itai T, Adachi M, Nagata S. Downregulation of Fas ligand by shedding. Nat Med. 1998;4:31\u20136. https:\/\/doi.org\/10.1038\/nm0198-031.","journal-title":"Nat Med"},{"key":"9756_CR157","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1034\/j.1399-3089.2002.01114.x","volume":"9","author":"S Tsuyuki","year":"2002","unstructured":"Tsuyuki S, Kono M, Bloom ET. Cloning and potential utility of porcine Fas ligand: overexpression in porcine endothelial cells protects them from attack by human cytolytic cells. Xenotransplantation. 2002;9:410\u201321. https:\/\/doi.org\/10.1034\/j.1399-3089.2002.01114.x.","journal-title":"Xenotransplantation"},{"key":"9756_CR158","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1161\/01.ATV.20.2.309","volume":"20","author":"M Sata","year":"2000","unstructured":"Sata M, Suhara T, Walsh K. Vascular endothelial cells and smooth muscle cells differ in expression of Fas and Fas ligand and in sensitivity to Fas ligand\u2013induced cell death: implications for vascular disease and therapy. Arterioscler Thromb Vasc Biol. 2000;20:309\u201316. https:\/\/doi.org\/10.1161\/01.ATV.20.2.309.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"9756_CR159","doi-asserted-by":"publisher","first-page":"14924","DOI":"10.1074\/jbc.M100819200","volume":"276","author":"DD Bannerman","year":"2001","unstructured":"Bannerman DD, Tupper JC, Ricketts WA, Bennett CF, Winn RK, Harlan JM. A constitutive cytoprotective pathway protects endothelial cells from lipopolysaccharide-induced apoptosis. J Biol Chem. 2001;276:14924\u201332. https:\/\/doi.org\/10.1074\/jbc.M100819200.","journal-title":"J Biol Chem"},{"key":"9756_CR160","first-page":"871","volume":"137","author":"RH Hruban","year":"1990","unstructured":"Hruban RH, Beschorner WE, Baumgartner WA, Augustine SM, Ren H, Reitz BA, et al. Accelerated arteriosclerosis in heart transplant recipients is associated with a T-lymphocyte-mediated endothelialitis. Am J Pathol. 1990;137:871\u201382.","journal-title":"Am J Pathol"},{"key":"9756_CR161","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1172\/JCI3531","volume":"102","author":"M Sata","year":"1998","unstructured":"Sata M, Walsh K. Oxidized LDL activates fas-mediated endothelial cell apoptosis. J Clin Invest. 1998;102:1682\u20139. https:\/\/doi.org\/10.1172\/JCI3531.","journal-title":"J Clin Invest"},{"key":"9756_CR162","doi-asserted-by":"publisher","first-page":"33103","DOI":"10.1074\/jbc.273.50.33103","volume":"273","author":"M Sata","year":"1998","unstructured":"Sata M, Walsh K. Endothelial cell apoptosis induced by oxidized LDL is associated with the down-regulation of the cellular caspase inhibitor FLIP. J Biol Chem. 1998;273:33103\u20136. https:\/\/doi.org\/10.1074\/jbc.273.50.33103.","journal-title":"J Biol Chem"},{"key":"9756_CR163","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1182\/blood-2007-10-119552","volume":"112","author":"R Stefanescu","year":"2008","unstructured":"Stefanescu R, Bassett D, Modarresi R, Santiago F, Fakruddin M, Laurence J. Synergistic interactions between interferon-\u03b3 and TRAIL modulate c-FLIP in endothelial cells, mediating their lineage-specific sensitivity to thrombotic thrombocytopenic purpura plasma\u2013associated apoptosis. Blood. 2008;112:340\u20139. https:\/\/doi.org\/10.1182\/blood-2007-10-119552.","journal-title":"Blood"},{"key":"9756_CR164","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.4049\/jimmunol.175.3.1858","volume":"175","author":"JH Li","year":"2005","unstructured":"Li JH, Pober JS. The cathepsin B death pathway contributes to TNF plus IFN-\u03b3-mediated human endothelial injury. J Immunol. 2005;175:1858\u201366. https:\/\/doi.org\/10.4049\/jimmunol.175.3.1858.","journal-title":"J Immunol"},{"key":"9756_CR165","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1016\/S0002-9440(10)64424-0","volume":"161","author":"JH Li","year":"2002","unstructured":"Li JH, Kluger MS, Madge LA, Zheng L, Bothwell ALM, Pober JS. Interferon-\u03b3 augments CD95(APO-1\/Fas) and pro-caspase-8 expression and sensitizes human vascular endothelial cells to CD95-mediated apoptosis. Am J Pathol. 2002;161:1485\u201395. https:\/\/doi.org\/10.1016\/S0002-9440(10)64424-0.","journal-title":"Am J Pathol"},{"key":"9756_CR166","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1161\/01.RES.86.10.1038","volume":"86","author":"S-W Chan","year":"2000","unstructured":"Chan S-W, Hegyi L, Scott S, Cary NRB, Weissberg PL, Bennett MR. Sensitivity to Fas-mediated apoptosis is determined below receptor level in human vascular smooth muscle cells. Circ Res. 2000;86:1038\u201346. https:\/\/doi.org\/10.1161\/01.RES.86.10.1038.","journal-title":"Circ Res"},{"key":"9756_CR167","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.2353\/ajpath.2006.050473","volume":"168","author":"D Rosner","year":"2006","unstructured":"Rosner D, Stoneman V, Littlewood T, McCarthy N, Figg N, Wang Y, et al. Interferon-\u03b3 induces Fas trafficking and sensitization to apoptosis in vascular smooth muscle cells via a PI3K- and Akt-dependent mechanism. Am J Pathol. 2006;168:2054\u201363. https:\/\/doi.org\/10.2353\/ajpath.2006.050473.","journal-title":"Am J Pathol"},{"key":"9756_CR168","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/S0002-9440(10)64599-3","volume":"157","author":"J-F L\u00e9gar\u00e9","year":"2000","unstructured":"L\u00e9gar\u00e9 J-F, Issekutz T, Lee TDG, Hirsch G. CD8\u2009+\u2009T lymphocytes mediate destruction of the vascular media in a model of chronic rejection. Am J Pathol. 2000;157:859\u201365. https:\/\/doi.org\/10.1016\/S0002-9440(10)64599-3.","journal-title":"Am J Pathol"},{"key":"9756_CR169","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.trim.2009.10.004","volume":"22","author":"M Hart-Matyas","year":"2010","unstructured":"Hart-Matyas M, Nejat S, Jordan JL, Hirsch GM, Lee TDG. IFN-\u03b3 and Fas\/FasL pathways cooperate to induce medial cell loss and neointimal lesion formation in allograft vasculopathy. Transpl Immunol. 2010;22:157\u201364. https:\/\/doi.org\/10.1016\/j.trim.2009.10.004.","journal-title":"Transpl Immunol"},{"key":"9756_CR170","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1097\/01.MP.0000067424.12280.BC","volume":"16","author":"JC Choy","year":"2003","unstructured":"Choy JC, McDonald PC, Suarez AC, Hung VHY, Wilson JE, McManus BM, et al. Granzyme B in atherosclerosis and transplant vascular disease: association with cell death and atherosclerotic disease severity. Mod Pathol. 2003;16:460\u201370. https:\/\/doi.org\/10.1097\/01.MP.0000067424.12280.BC.","journal-title":"Mod Pathol"},{"key":"9756_CR171","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1038\/s41409-022-01698-3","volume":"57","author":"G Rodionov","year":"2022","unstructured":"Rodionov G, Rosenzwaig M, Tzadok MS, Kvint M, Gevir E, Zorde-Khvalevsky E, et al. Short treatment of peripheral blood cells product with Fas ligand using closed automated cell processing system significantly reduces immune cell reactivity of the graft in vitro and in vivo. Bone Marrow Transplant. 2022;57:1250\u20139. https:\/\/doi.org\/10.1038\/s41409-022-01698-3.","journal-title":"Bone Marrow Transplant"},{"key":"9756_CR172","doi-asserted-by":"publisher","first-page":"103","DOI":"10.5114\/ceh.2019.85076","volume":"5","author":"K Shams","year":"2019","unstructured":"Shams K, Kalantar K, Karimi MH, Nasiri M, Afshari A, Amirghofran Z. Fas, FasL and Foxp3 gene expression in post-liver transplant autoimmune hepatitis patients with and without acute rejection. Clin Exp Hepatol. 2019;5:103\u20138. https:\/\/doi.org\/10.5114\/ceh.2019.85076.","journal-title":"Clin Exp Hepatol"},{"key":"9756_CR173","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-018-0804-6","volume":"9","author":"R Yang","year":"2018","unstructured":"Yang R, Yu T, Liu D, Shi S, Zhou Y. Hydrogen sulfide promotes immunomodulation of gingiva-derived mesenchymal stem cells via the Fas\/FasL coupling pathway. Stem Cell Res Ther. 2018;9:62. https:\/\/doi.org\/10.1186\/s13287-018-0804-6.","journal-title":"Stem Cell Res Ther"},{"key":"9756_CR174","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1016\/j.jhep.2014.06.016","volume":"61","author":"M Riccio","year":"2014","unstructured":"Riccio M, Carnevale G, Cardinale V, Gibellini L, De Biasi S, Pisciotta A, et al. The Fas\/Fas ligand apoptosis pathway underlies immunomodulatory properties of human biliary tree stem\/progenitor cells. J Hepatol. 2014;61:1097\u2013105. https:\/\/doi.org\/10.1016\/j.jhep.2014.06.016.","journal-title":"J Hepatol"},{"key":"9756_CR175","doi-asserted-by":"publisher","first-page":"3143","DOI":"10.1016\/j.transproceed.2004.11.091","volume":"36","author":"HA De Groot-Kruseman","year":"2004","unstructured":"De Groot-Kruseman HA, Baan CC, Zondervan PE, De Weger RA, Niesters HGM, Balk AHMM, et al. Apoptotic death of infiltrating cells in human cardiac allografts is regulated by IL-2, FASL, and FLIP. Transplant Proc. 2004;36:3143\u20138. https:\/\/doi.org\/10.1016\/j.transproceed.2004.11.091.","journal-title":"Transplant Proc"},{"key":"9756_CR176","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1006\/exer.2002.2044","volume":"75","author":"Y Sano","year":"2002","unstructured":"Sano Y, Yamada J, Ishino Y, Adachi W, Kawasaki S, Suzuki T, et al. Non-cleavable mutant Fas ligand transfection of donor cornea abrogates ocular immune privilege. Exp Eye Res. 2002;75:475\u201383. https:\/\/doi.org\/10.1006\/exer.2002.2044.","journal-title":"Exp Eye Res"},{"key":"9756_CR177","doi-asserted-by":"publisher","first-page":"S324","DOI":"10.1007\/s001470050353","volume":"13","author":"RA Schmid","year":"2000","unstructured":"Schmid RA, Stammberger U, Hillinger S, Gaspert A, Boasquevisque CH, Malipiero U, et al. Fas ligand gene transfer combined with low dose cyclosporine A reduces acute lung allograft rejection. Transpl Int. 2000;13:S324. https:\/\/doi.org\/10.1007\/s001470050353.","journal-title":"Transpl Int"},{"key":"9756_CR178","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-04688-x","volume":"13","author":"V Risso","year":"2022","unstructured":"Risso V, Lafont E, Le Gallo M. Therapeutic approaches targeting CD95L\/CD95 signaling in cancer and autoimmune diseases. Cell Death Dis. 2022;13:248. https:\/\/doi.org\/10.1038\/s41419-022-04688-x.","journal-title":"Cell Death Dis"},{"key":"9756_CR179","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1158\/1541-7786.MCR-17-0563","volume":"16","author":"J Blaes","year":"2018","unstructured":"Blaes J, Thom\u00e9 CM, Pfenning P-N, R\u00fcbmann P, Sahm F, Wick A, et al. Inhibition of CD95\/CD95L (FAS\/FASLG) signaling with APG101 prevents invasion and enhances radiation therapy for glioblastoma. Mol Cancer Res. 2018;16:767\u201376. https:\/\/doi.org\/10.1158\/1541-7786.MCR-17-0563.","journal-title":"Mol Cancer Res"},{"key":"9756_CR180","doi-asserted-by":"publisher","first-page":"4669","DOI":"10.1182\/blood.V124.21.4669.4669","volume":"124","author":"E launiger-L\u00f6rsch","year":"2014","unstructured":"launiger-L\u00f6rsch E, Luft T, Fey S, Obl\u00e4nder J, Brendel S, Pressler J, et al. The Fas ligand inhibitor APG101 in transfusion dependent patients with low risk MDS: interim results from a phase I study. Blood. 2014;124:4669\u20134669. https:\/\/doi.org\/10.1182\/blood.V124.21.4669.4669.","journal-title":"Blood"},{"key":"9756_CR181","doi-asserted-by":"publisher","DOI":"10.1038\/srep30816","volume":"6","author":"GL Coe","year":"2016","unstructured":"Coe GL, Redd PS, Paschall AV, Lu C, Gu L, Cai H, et al. Ceramide mediates FasL-induced caspase 8 activation in colon carcinoma cells to enhance FasL-induced cytotoxicity by tumor-specific cytotoxic T lymphocytes. Sci Rep. 2016;6:30816. https:\/\/doi.org\/10.1038\/srep30816.","journal-title":"Sci Rep"},{"key":"9756_CR182","doi-asserted-by":"publisher","first-page":"7553","DOI":"10.1074\/jbc.M211229200","volume":"278","author":"S Jodo","year":"2003","unstructured":"Jodo S, Kung JT, Xiao S, Chan DV, Kobayashi S, Tateno M, et al. Anti-CD95-induced lethality requires radioresistant Fc\u03b3RII+ cells. J Biol Chem. 2003;278:7553\u20137. https:\/\/doi.org\/10.1074\/jbc.M211229200.","journal-title":"J Biol Chem"},{"key":"9756_CR183","doi-asserted-by":"publisher","first-page":"562","DOI":"10.4049\/jimmunol.171.2.562","volume":"171","author":"Y Xu","year":"2003","unstructured":"Xu Y, Szalai AJ, Zhou T, Zinn KR, Chaudhuri TR, Li X, et al. Fc\u03b3Rs modulate cytotoxicity of anti-Fas antibodies: implications for agonistic antibody-based therapeutics. J Immunol. 2003;171:562\u20138. https:\/\/doi.org\/10.4049\/jimmunol.171.2.562.","journal-title":"J Immunol"},{"key":"9756_CR184","doi-asserted-by":"publisher","unstructured":"Hamad ARAR, Arcara K, Uddin S, Donner T. The potential of Fas ligand (apoptosis-inducing molecule) as an unconventional therapeutic target in type 1 diabetes. Front Immunol 2012;3. https:\/\/doi.org\/10.3389\/fimmu.2012.00196.","DOI":"10.3389\/fimmu.2012.00196"},{"key":"9756_CR185","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.tcb.2011.09.003","volume":"22","author":"M Maceyka","year":"2012","unstructured":"Maceyka M, Harikumar KB, Milstien S, Spiegel S. Sphingosine-1-phosphate signaling and its role in disease. Trends Cell Biol. 2012;22:50\u201360. https:\/\/doi.org\/10.1016\/j.tcb.2011.09.003.","journal-title":"Trends Cell Biol"},{"key":"9756_CR186","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.immuni.2016.06.028","volume":"45","author":"A Poissonnier","year":"2016","unstructured":"Poissonnier A, Sans\u00e9au D, Le Gallo M, Malleter M, Levoin N, Viel R, et al. CD95-mediated calcium signaling promotes T helper 17 trafficking to inflamed organs in lupus-prone mice. Immunity. 2016;45:209\u201323. https:\/\/doi.org\/10.1016\/j.immuni.2016.06.028.","journal-title":"Immunity"},{"key":"9756_CR187","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1038\/nrd3248","volume":"9","author":"V Brinkmann","year":"2010","unstructured":"Brinkmann V, Billich A, Baumruker T, Heining P, Schmouder R, Francis G, et al. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov. 2010;9:883\u201397. https:\/\/doi.org\/10.1038\/nrd3248.","journal-title":"Nat Rev Drug Discov"},{"key":"9756_CR188","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1084\/jem.20020633","volume":"196","author":"Y Nakamoto","year":"2002","unstructured":"Nakamoto Y, Kaneko S, Fan H, Momoi T, Tsutsui H, Nakanishi K, et al. Prevention of hepatocellular carcinoma development associated with chronic hepatitis by anti-Fas ligand antibody therapy. J Exp Med. 2002;196:1105\u201311. https:\/\/doi.org\/10.1084\/jem.20020633.","journal-title":"J Exp Med"},{"key":"9756_CR189","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1084\/jem.194.2.155","volume":"194","author":"VM Borges","year":"2001","unstructured":"Borges VM, Falc\u00e3o H, Leite-J\u00fanior JH, Alvim L, Teixeira GP, Russo M, et al. FAS ligand triggers pulmonary silicosis. J Exp Med. 2001;194:155\u201364. https:\/\/doi.org\/10.1084\/jem.194.2.155.","journal-title":"J Exp Med"},{"key":"9756_CR190","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/nm1007","volume":"10","author":"D Demjen","year":"2004","unstructured":"Demjen D, Klussmann S, Kleber S, Zuliani C, Stieltjes B, Metzger C, et al. Neutralization of CD95 ligand promotes regeneration and functional recovery after spinal cord injury. Nat Med. 2004;10:389\u201395. https:\/\/doi.org\/10.1038\/nm1007.","journal-title":"Nat Med"},{"key":"9756_CR191","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1093\/intimm\/11.6.925","volume":"11","author":"K Miwa","year":"1999","unstructured":"Miwa K, Hashimoto H, Yatomi T, Nakamura N, Nagata S, Suda T. Therapeutic effect of an anti-Fas ligand mAb on lethal graft-versus-host disease. Int Immunol. 1999;11:925\u201331. https:\/\/doi.org\/10.1093\/intimm\/11.6.925.","journal-title":"Int Immunol"},{"key":"9756_CR192","doi-asserted-by":"publisher","unstructured":"Hammam O, Mahmoud O, Zahran M, Aly S, Hosny K, Helmy A, et al. The Role of Fas\/Fas Ligand System in the Pathogenesis of Liver Cirrhosis and Hepatocellular Carcinoma. Hepat Mon 2012;12. https:\/\/doi.org\/10.5812\/hepatmon.6132.","DOI":"10.5812\/hepatmon.6132"},{"key":"9756_CR193","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1007\/s10495-008-0234-5","volume":"13","author":"H Nakajima","year":"2008","unstructured":"Nakajima H, Mizuta N, Fujiwara I, Sakaguchi K, Ogata H, Magae J, et al. Blockade of the Fas\/Fas ligand interaction suppresses hepatocyte apoptosis in ischemia-reperfusion rat liver. Apoptosis. 2008;13:1013\u201321. https:\/\/doi.org\/10.1007\/s10495-008-0234-5.","journal-title":"Apoptosis"},{"key":"9756_CR194","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1128\/MCB.23.4.1428-1440.2003","volume":"23","author":"N Holler","year":"2003","unstructured":"Holler N, Tardivel A, Kovacsovics-Bankowski M, Hertig S, Gaide O, Martinon F, et al. Two adjacent trimeric Fas ligands are required for Fas signaling and formation of a death-inducing signaling complex. Mol Cell Biol. 2003;23:1428\u201340. https:\/\/doi.org\/10.1128\/MCB.23.4.1428-1440.2003.","journal-title":"Mol Cell Biol"},{"key":"9756_CR195","doi-asserted-by":"publisher","first-page":"8176","DOI":"10.4049\/jimmunol.180.12.8176","volume":"180","author":"A Krippner-Heidenreich","year":"2008","unstructured":"Krippner-Heidenreich A, Grunwald I, Zimmermann G, K\u00fchnle M, Gerspach J, Sterns T, et al. Single-chain TNF, a TNF derivative with enhanced stability and antitumoral activity. J Immunol. 2008;180:8176\u201383. https:\/\/doi.org\/10.4049\/jimmunol.180.12.8176.","journal-title":"J Immunol"},{"key":"9756_CR196","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1038\/sj.bjc.6604736","volume":"99","author":"B Rikhof","year":"2008","unstructured":"Rikhof B, Van Der Graaf WTA, Meijer C, Le PTK, Meersma GJ, De Jong S, et al. Abundant Fas expression by gastrointestinal stromal tumours may serve as a therapeutic target for MegaFasL. Br J Cancer. 2008;99:1600\u20136. https:\/\/doi.org\/10.1038\/sj.bjc.6604736.","journal-title":"Br J Cancer"},{"key":"9756_CR197","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/cdd.2009.141","volume":"17","author":"I Verbrugge","year":"2010","unstructured":"Verbrugge I, Maas C, Heijkoop M, Verheij M, Borst J. Radiation and anticancer drugs can facilitate mitochondrial bypass by CD95\/Fas via c-FLIP downregulation. Cell Death Differ. 2010;17:551\u201361. https:\/\/doi.org\/10.1038\/cdd.2009.141.","journal-title":"Cell Death Differ"},{"key":"9756_CR198","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.canlet.2010.12.019","volume":"332","author":"H Wajant","year":"2013","unstructured":"Wajant H, Gerspach J, Pfizenmaier K. Engineering death receptor ligands for cancer therapy. Cancer Lett. 2013;332:163\u201374. https:\/\/doi.org\/10.1016\/j.canlet.2010.12.019.","journal-title":"Cancer Lett"},{"key":"9756_CR199","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/sj.cdd.4402051","volume":"14","author":"I Watermann","year":"2007","unstructured":"Watermann I, Gerspach J, Lehne M, Seufert J, Schneider B, Pfizenmaier K, et al. Activation of CD95L fusion protein prodrugs by tumor-associated proteases. Cell Death Differ. 2007;14:765\u201374. https:\/\/doi.org\/10.1038\/sj.cdd.4402051.","journal-title":"Cell Death Differ"},{"key":"9756_CR200","doi-asserted-by":"publisher","unstructured":"Ramaswamy M, Clel SY, Cruz AC, Siegel RM. Many Checkpoints on the Road to Cell Death:Regulation of Fas\u2013FasL Interactions and Fas Signaling in Peripheral Immune Responses. In: Kalthoff H, editor. Death Recept. Cogn. Ligands Cancer, vol. 49, Berlin, Heidelberg: Springer Berlin Heidelberg; 2009, p. 17\u201347. https:\/\/doi.org\/10.1007\/400_2008_24.","DOI":"10.1007\/400_2008_24"},{"key":"9756_CR201","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.bcp.2009.04.032","volume":"78","author":"PB Raghavendra","year":"2009","unstructured":"Raghavendra PB, Pathak N, Manna SK. Novel role of thiadiazolidine derivatives in inducing cell death through Myc-Max, Akt, FKHR, and FasL pathway. Biochem Pharmacol. 2009;78:495\u2013503. https:\/\/doi.org\/10.1016\/j.bcp.2009.04.032.","journal-title":"Biochem Pharmacol"},{"key":"9756_CR202","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s00432-007-0340-8","volume":"134","author":"S Heikaus","year":"2008","unstructured":"Heikaus S, Matuszek KS, Suschek CV, Ramp U, Reinecke P, Grinstein E, et al. Paclitaxel (Taxol\u00ae)-induced apoptosis in human epithelioid sarcoma cell lines is enhanced by upregulation of CD95 ligand (FasL\/Apo-1L). J Cancer Res Clin Oncol. 2008;134:689\u201395. https:\/\/doi.org\/10.1007\/s00432-007-0340-8.","journal-title":"J Cancer Res Clin Oncol"},{"key":"9756_CR203","doi-asserted-by":"publisher","DOI":"10.2741\/3719","volume":"16","author":"A Amoroso","year":"2011","unstructured":"Amoroso A. Understanding rituximab function and resistance: implications for tailored therapy. Front Biosci. 2011;16:770. https:\/\/doi.org\/10.2741\/3719.","journal-title":"Front Biosci"},{"key":"9756_CR204","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1046\/j.1440-1711.2002.01068.x","volume":"80","author":"S Maher","year":"2002","unstructured":"Maher S, Toomey D, Condron C, Bouchier-Hayes D. Activation\u2010induced cell death: the controversial role of Fas and Fas ligand in immune privilege and tumour counterattack. Immunol Cell Biol. 2002;80:131\u20137. https:\/\/doi.org\/10.1046\/j.1440-1711.2002.01068.x.","journal-title":"Immunol Cell Biol"},{"key":"9756_CR205","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16020290","volume":"16","author":"K Chung","year":"2024","unstructured":"Chung K, Ullah I, Yi Y, Kang E, Yun G, Heo S, et al. Intranasal delivery of anti-apoptotic siRNA complexed with Fas-signaling blocking peptides attenuates cellular apoptosis in brain ischemia. Pharmaceutics. 2024;16:290. https:\/\/doi.org\/10.3390\/pharmaceutics16020290.","journal-title":"Pharmaceutics"},{"key":"9756_CR206","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2024.103339","volume":"149","author":"Y Feng","year":"2024","unstructured":"Feng Y, Deyanat-Yazdi G, Newburn K, Potter S, Wortinger M, Ramirez M, et al. PD-1 antibody interactions with Fc gamma receptors enable PD-1 agonism to inhibit T cell activation \u2013 therapeutic implications for autoimmunity. J Autoimmun. 2024;149:103339. https:\/\/doi.org\/10.1016\/j.jaut.2024.103339.","journal-title":"J Autoimmun"}],"container-title":["Immunologic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-026-09756-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12026-026-09756-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-026-09756-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T22:03:29Z","timestamp":1773698609000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12026-026-09756-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,16]]},"references-count":206,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9756"],"URL":"https:\/\/doi.org\/10.1007\/s12026-026-09756-4","relation":{},"ISSN":["1559-0755"],"issn-type":[{"value":"1559-0755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,16]]},"assertion":[{"value":"25 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"28"}}